Form 8-K · Current report
News Corp 8-K, filed Oct 1, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000213
Summary
News Corp disclosed to the Australian Securities Exchange that it bought back 62,323 shares of Class A common stock on 30 September 2026 for US$1,796,335.83, bringing cumulative repurchases under its 2025 Repurchase Program to about US$506.9 million of the US$1 billion authorized. The program covers News Corp's Nasdaq-listed Class A and Class B common stock and is intended to enhance shareholder value.
Key points
- News Corp repurchased 62,323 shares of Class A common stock on 30 September 2026 for US$1,796,335.83, at prices between US$28.51 and US$28.96.
- Cumulative repurchases under the program total 12,609,003 shares for US$330,540,141.06, at prices from US$22.20 to US$31.58.
- News Corp has bought approximately US$506,862,353 of Class A and Class B shares under the 2025 Repurchase Program, which authorizes up to US$1 billion.
- No ASX-listed CDIs will be repurchased; the program covers Nasdaq-listed Class A and Class B stock.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.